918 related articles for article (PubMed ID: 15804725)
21. Delivery of a GDNF gene into the substantia nigra after a progressive 6-OHDA lesion maintains functional nigrostriatal connections.
Kozlowski DA; Connor B; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2000 Nov; 166(1):1-15. PubMed ID: 11031079
[TBL] [Abstract][Full Text] [Related]
22. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
23. Quantitative analyses of GFRalpha-1 and GFRalpha-2 mRNAs and tyrosine hydroxylase protein in the nigrostriatal system reveal bilateral compensatory changes following unilateral 6-OHDA lesions in the rat.
Kozlowski DA; Miljan EA; Bremer EG; Harrod CG; Gerin C; Connor B; George D; Larson B; Bohn MC
Brain Res; 2004 Aug; 1016(2):170-81. PubMed ID: 15246853
[TBL] [Abstract][Full Text] [Related]
24. Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat--evaluation of time-course and LGR8 expression.
Sedaghat K; Finkelstein DI; Gundlach AL
Brain Res; 2009 May; 1271():83-94. PubMed ID: 19328193
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
Ghorayeb I; Puschban Z; Fernagut PO; Scherfler C; Rouland R; Wenning GK; Tison F
Exp Neurol; 2001 Jan; 167(1):133-47. PubMed ID: 11161601
[TBL] [Abstract][Full Text] [Related]
26. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
[TBL] [Abstract][Full Text] [Related]
27. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
28. Expression of S-100 protein is related to neuronal damage in MPTP-treated mice.
Muramatsu Y; Kurosaki R; Watanabe H; Michimata M; Matsubara M; Imai Y; Araki T
Glia; 2003 May; 42(3):307-13. PubMed ID: 12673835
[TBL] [Abstract][Full Text] [Related]
29. Temporal and spatial increase of astroglial basic fibroblast growth factor synthesis after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine neurons.
Chadi G; Cao Y; Pettersson RF; Fuxe K
Neuroscience; 1994 Aug; 61(4):891-910. PubMed ID: 7838386
[TBL] [Abstract][Full Text] [Related]
30. Transplantation of mesencephalic cell suspension in dopamine-denervated striatum of the rat.I. Effects on spontaneous activity of striatal neurons.
Di Loreto S; Florio T; Capozzo A; Napolitano A; Adorno D; Scarnati E
Exp Neurol; 1996 Apr; 138(2):318-26. PubMed ID: 8620930
[TBL] [Abstract][Full Text] [Related]
31. Ibotenic acid-induced lesions of striatal target and projection neurons: ultrastructural manifestations in dopaminergic and non-dopaminergic neurons and in glia.
Smith DE; Saji M; Joh TH; Reis DJ; Pickel VM
Histol Histopathol; 1987 Jul; 2(3):251-63. PubMed ID: 2908792
[TBL] [Abstract][Full Text] [Related]
32. The 6-hydroxydopamine-induced nigrostriatal neurodegeneration produces microglia-like NG2 glial cells in the rat substantia nigra.
Kitamura Y; Inden M; Minamino H; Abe M; Takata K; Taniguchi T
Glia; 2010 Nov; 58(14):1686-700. PubMed ID: 20629191
[TBL] [Abstract][Full Text] [Related]
33. Increased tyrosine hydroxylase expression accompanied by glial changes within the non-lesioned hemisphere in the 6-hydroxydopamine model of Parkinson's disease.
Schlachetzki JC; Marxreiter F; Regensburger M; Kulinich A; Winner B; Winkler J
Restor Neurol Neurosci; 2014; 32(4):447-62. PubMed ID: 24604006
[TBL] [Abstract][Full Text] [Related]
34. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
35. Induction of c-Jun and suppression of CREB transcription factor proteins in axotomized neurons of substantia nigra and covariation with tyrosine hydroxylase.
Brecht S; Gass P; Anton F; Bravo R; Zimmermann M; Herdegen T
Mol Cell Neurosci; 1994 Oct; 5(5):431-41. PubMed ID: 7820366
[TBL] [Abstract][Full Text] [Related]
36. Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway.
Meshul CK; Cogen JP; Cheng HW; Moore C; Krentz L; McNeill TH
Exp Neurol; 2000 Sep; 165(1):191-206. PubMed ID: 10964498
[TBL] [Abstract][Full Text] [Related]
37. Intrapallidal injection of 6-hydroxydopamine induced changes in dopamine innervation and neuronal activity of globus pallidus.
Bouali-Benazzouz R; Tai CH; Chetrit J; Benazzouz A
Neuroscience; 2009 Dec; 164(2):588-96. PubMed ID: 19628021
[TBL] [Abstract][Full Text] [Related]
38. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
39. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration.
Wenning GK; Granata R; Laboyrie PM; Quinn NP; Jenner P; Marsden CD
Mov Disord; 1996 Sep; 11(5):522-32. PubMed ID: 8866493
[TBL] [Abstract][Full Text] [Related]
40. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
